½ÃÀ庸°í¼­
»óǰÄÚµå
1586004

CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå : ±¸¼º¿ä¼Ò, ÀÀ¿ë ºÐ¾ß, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

CRISPR & Cas Genes Market by Component (Product, Service), Application (Agricultural, Biomedical), End-user - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 197 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀåÀº 2023³â¿¡ 38¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 50¾ï 4,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 32.40%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 272¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀåÀº »ý¹°Ã¼ÀÇ DNA¸¦ Á¤¹ÐÇÏ°Ô ±³Á¤ÇÏ¿© »ý¸í°øÇÐ, ³ó¾÷ ¹× ÀÇÇÐ ¿¬±¸¿¡ º¯È­¸¦ °¡Á®¿À´Â À¯ÀüÀÚ ÆíÁý ±â¼úÀ» Áß½ÉÀ¸·Î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº °³·®µÈ ÀÛ¹° ǰÁ¾, À¯Àü¼º Áúȯ¿¡ ´ëÇÑ °í±Þ Ä¡·á ¼Ö·ç¼Ç, °£¼ÒÈ­µÈ À¯ÀüÀÚ ÆíÁý ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ÀÇÇØ Å©°Ô °ßÀεǰí ÀÖ½À´Ï´Ù. ÀÀ¿ë ºÐ¾ß¿¡¼­´Â CRISPR ±â¼úÀÌ Áúº´À» Ä¡·áÇϱâ À§ÇÑ ÀÇ·á¿ë À¯ÀüÀÚ Ä¡·áºÎÅÍ ÀÛ¹°ÀÇ È¸º¹·Â°ú ¼öÈ®·®À» Çâ»ó½ÃŰ´Â ³ó¾÷¿ë ÀÀ¿ë ºÐ¾ß·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÃÖÁ¾ »ç¿ë ºÐ¾ß´Â Á¦¾à, ÀÇ·á, ³ó¾÷, »ý¸í°øÇÐ ±â¾÷ µî ±¤¹üÀ§ÇÕ´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â Á¤È®¼º°ú È¿À²¼ºÀ» ³ôÀÌ´Â ±â¼ú ¹ßÀü, À¯ÀüüÇÐ ºÐ¾ßÀÇ ÀÚ±Ý Á¶´Þ ¹× ¹Î°ü ÆÄÆ®³Ê½Ê Áõ°¡, Ä¡·á °³¹ß¿¡¼­ CRISPR ¼Ö·ç¼ÇÀÇ ¼ö¿ë È®´ë, CRISPR ±â¹Ý Áø´Ü, ³ó¾÷ ºÐ¾ßÀÇ ¹ßÀü, °³ÀÎ ¸ÂÃãÇü ÀÇ·á ¹× ÇÕ¼º »ý¹°Çп¡ÀÇ Àû¿ë °¡´É¼º µîÀÌ ÀÖ½À´Ï´Ù. ÀáÀç·Â¿¡¼­ Å« ºñÁî´Ï½º ±âȸ°¡ âÃâµÇ°í ÀÖÀ¸¸ç, ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ ¹× Çõ½ÅÀ» ÃËÁøÇϱâ À§ÇÑ Àü·«Àû Çù·Â °ü°è Çü¼ºÀÌ ±ÇÀåµË´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 38¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 50¾ï 4,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 272¾ï 1,000¸¸ ´Þ·¯
CAGR(%) 32.40%

±×·¯³ª À¯ÀüÀÚ ÆíÁý¿¡ ´ëÇÑ À±¸®Àû ¹®Á¦, º¹ÀâÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, ÀǵµÇÏÁö ¾ÊÀº À¯ÀüÀÚ º¯ÀÌ·Î À̾îÁú ¼ö ÀÖ´Â ¿ÀÇÁŸ°Ù È¿°úÀÇ °¡´É¼º µî ¿©·¯ °¡Áö ¹®Á¦°¡ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÁöÀûÀç»ê±Ç °ü·Ã ºÐÀïÀÌ ½ÃÀå ¿ªÇÐÀ» Á¦ÇÑÇÒ °¡´É¼ºµµ ÀÖ½À´Ï´Ù. µ¥ÀÌÅÍ °øÀ¯ÀÇ Åõ¸í¼º, CRISPR-Cas ½Ã½ºÅÛÀÇ Ãæ½Çµµ Çâ»ó, °­·ÂÇÑ À±¸®Àû °¡À̵å¶óÀÎÀÇ °³¹ßÀ» ÅëÇØ ÀÌ·¯ÇÑ Á¦ÇÑÀ» ÇØ°áÇÏ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. À¯¸ÁÇÑ Çõ½ÅÀÇ ±æÀº ƯÀ̼º°ú ¾ÈÀü¼ºÀ» Çâ»ó½ÃŲ Â÷¼¼´ë CRISPR ½Ã½ºÅÛÀÇ °³¹ß, ¹ÙÀÌ¿À¿¬·á¿¡ÀÇ Àû¿ë, º¹ÀâÇÑ ÇüÁú Á¶ÀÛÀ» À§ÇÑ »õ·Î¿î À¯ÀüÀÚ ÆíÁý µµ±¸ µîÀÔ´Ï´Ù. CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀåÀº ±Þ¼ÓÇÑ ±â¼ú ¹ßÀü°ú ´Ù¾çÇÑ ºÐ¾ß·ÎÀÇ ÀÀ¿ë °¡´É¼ºÀÌ ³ôÀº ¸¸Å­, Àû±ØÀûÀÎ ±ÔÁ¦ º¯È­ ÃßÀû, Á¤Ã¥ ´ëÈ­ Âü¿©, À±¸®Àû ÀÚ¹® ±×·ì Âü¿© µî Àû±ØÀûÀÎ Á¢±ÙÀÌ À¯¸®ÇÏ°Ô ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇÏÁö¸¸ ±× ÀáÀç·ÂÀ» ÃæºÐÈ÷ ¹ßÈÖÇϱâ À§Çؼ­´Â ±ÔÁ¦Àû, À±¸®Àû Ãø¸é¿¡¼­ ¿©·¯ °¡Áö °úÁ¦¸¦ ±Øº¹ÇØ¾ß ÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®¸¦ °ø°³ÇÕ´Ï´Ù.

CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ¸·Î ÀÎÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«Àû ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • »ùÇà Á¶Á÷ ½ºÅ©¸®´×À» À§ÇÑ CRISPR ±â¹Ý Áø´Ü ºÐ¼®¹ý °³¹ß
    • À¯Àü¼º ÁúȯÀÇ ³ôÀº À¯º´·ü
    • ½Å¾à °³¹ß, »ýÀÇÇÐ ¿¬±¸, ºñÇüÁúÀüȯ ÃâÇ÷¿¡ ´ëÇÑ ÀÀ¿ë Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • CRISPR ±â¼úÀÇ ¿ÀÇÁ Ÿ°Ù È¿°ú
  • ½ÃÀå ±âȸ
    • Ç×-CRISPR ´Ü¹éÁúÀÇ ÁøÈ­
    • CRISPR-Cas À¯ÀüÀÚÀÇ ½Å±Ô ÀÀ¿ëÀ» À§ÇÑ ¿¬±¸ °³¹ß
  • ½ÃÀå °úÁ¦
    • ƯÇã ÇöȲ ¹× ºÐÀï

Portre's Five Forces: CRISPR°ú Cas À¯ÀüÀÚ ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû Æ÷Áö¼Å´×À» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀåÀÇ Àü·«Àû ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚµéÀÌ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ µµ¿òÀÌ µÇ´Â Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå : ÄÄÆ÷³ÍÆ®º°

  • Á¦Ç°
    • Ç×ü
    • µðÀÚÀÎ Åø
    • ŰƮ ¹× È¿¼Ò
      • DNA-Free Cas
      • Vector-Based Cas
    • ¶óÀ̺귯¸®
  • ¼­ºñ½º
    • ¼¼Æ÷ÁÖ ¿£Áö´Ï¾î¸µ
    • DNA ÇÕ¼º
    • gRNA ¼³°è
    • ¹Ì»ý¹° À¯ÀüÀÚ ÆíÁý

Á¦7Àå CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå : ¿ëµµº°

  • ³ó¾÷
  • ¹ÙÀÌ¿À¸ÞµðÄÃ
    • Áúȯ ¸ðµ¨ ¿¬±¸
    • ¿¡ÇÇÁ¦³×ƽ½º
    • ±â´É À¯ÀüüÇÐ
    • À¯Àüü °øÇÐ

Á¦8Àå CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • Çмú±â°ü ¹× Á¤ºÎ ¿¬±¸±â°ü
  • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ¹× Á¦¾àȸ»ç
  • °è¾à ¿¬±¸±â°ü

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • AstraZeneca plc
  • Beam Therapeutics Inc.
  • Beckman Coulter, Inc.
  • Calyxt, Inc.
  • Caribou Biosciences, Inc.
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Editas Medicine, Inc.
  • Hera Biolabs
  • Horizon Discovery Group Plc
  • Inscripta, Inc.
  • Integrated Dna Technologies, Inc.
  • Intellia Therapeutics, Inc.
  • Lonza Group
  • Mammoth Biosciences
LSH

The CRISPR & Cas Genes Market was valued at USD 3.81 billion in 2023, expected to reach USD 5.04 billion in 2024, and is projected to grow at a CAGR of 32.40%, to USD 27.21 billion by 2030.

The CRISPR & Cas Genes market revolves around genome-editing technology, providing precise and targeted modifications in the DNA of living organisms, which is transforming biotechnology, agriculture, and medical research. This market is significantly driven by the rising demand for improved crop varieties, advanced therapeutic solutions for genetic disorders, and streamlined gene-editing methods. In application, CRISPR technology spans from medical gene therapy aimed at treating diseases to agricultural applications that enhance crop resilience and yield. End-use sectors show a broad range, including pharmaceuticals, medicine, agriculture, and biotechnology companies. Key growth factors include technological advancements enhancing precision and efficiency, increased funding and public-private partnerships in genomics, and a growing acceptance of CRISPR solutions in therapeutic developments. Significant opportunities arise from CRISPR-based diagnostics, agriculture sector advancements, and potential applications in personalized medicine and synthetic biology, with recommendations focusing on investing in R&D and forming strategic collaborations to foster innovation.

KEY MARKET STATISTICS
Base Year [2023] USD 3.81 billion
Estimated Year [2024] USD 5.04 billion
Forecast Year [2030] USD 27.21 billion
CAGR (%) 32.40%

However, challenges include ethical concerns regarding gene editing, complex regulatory frameworks, and the potential for off-target effects that could lead to unintentional genetic mutations. Furthermore, intellectual property disputes may limit market dynamics. Addressing these limitations through transparency in data sharing, enhancing CRISPR-Cas systems' fidelity, and developing robust ethical guidelines would be crucial. Promising avenues for innovation include developing next-generation CRISPR systems with improved specificity and safety, applications in biofuels, and novel gene-editing tools for complex traits manipulation. Given the market's evolving nature, a proactive approach in tracking regulatory changes, participating in policy dialogues, and engaging with ethical advisory groups can position companies advantageously. The CRISPR & Cas Genes market is poised for substantial growth, characterized by rapid technological developments and a high potential for cross-sectoral applications, yet it requires navigating numerous regulatory and ethical challenges to realize its full potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving CRISPR & Cas Genes Market

The CRISPR & Cas Genes Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Development of CRISPR-based diagnostic assays for sample tissue screening
    • High prevalence of genetic disorders
    • Rising application in drug discovery, biomedical research, and non-transgenic bleeding
  • Market Restraints
    • Off-target effects of CRISPR technology
  • Market Opportunities
    • Evolution of anti-CRISPR protein
    • Research and development for novel application of CRISPR-Cas genes
  • Market Challenges
    • Patent landscape and dispute

Porter's Five Forces: A Strategic Tool for Navigating the CRISPR & Cas Genes Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the CRISPR & Cas Genes Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the CRISPR & Cas Genes Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the CRISPR & Cas Genes Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the CRISPR & Cas Genes Market

A detailed market share analysis in the CRISPR & Cas Genes Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the CRISPR & Cas Genes Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the CRISPR & Cas Genes Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the CRISPR & Cas Genes Market

A strategic analysis of the CRISPR & Cas Genes Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the CRISPR & Cas Genes Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca plc, Beam Therapeutics Inc., Beckman Coulter, Inc., Calyxt, Inc., Caribou Biosciences, Inc., CRISPR Therapeutics AG, Danaher Corporation, Editas Medicine, Inc., Hera Biolabs, Horizon Discovery Group Plc, Inscripta, Inc., Integrated Dna Technologies, Inc., Intellia Therapeutics, Inc., Lonza Group, and Mammoth Biosciences.

Market Segmentation & Coverage

This research report categorizes the CRISPR & Cas Genes Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Component, market is studied across Product and Service. The Product is further studied across Antibodies, Design Tool, Kits & Enzymes, and Libraries. The Kits & Enzymes is further studied across DNA-Free Cas and Vector-Based Cas. The Service is further studied across Cell Line Engineering, DNA Synthesis, gRNA Design, and Microbial Gene Editing.
  • Based on Application, market is studied across Agricultural and Biomedical. The Biomedical is further studied across Disease Model Studies, Epigenetics, Functional Genomics, and Genome Engineering.
  • Based on End-user, market is studied across Academics & Government Research Institutes, Biotechnology & Pharmaceutical Companies, and Contract Research Organizations.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Development of CRISPR-based diagnostic assays for sample tissue screening
      • 5.1.1.2. High prevalence of genetic disorders
      • 5.1.1.3. Rising application in drug discovery, biomedical research, and non-transgenic bleeding
    • 5.1.2. Restraints
      • 5.1.2.1. Off-target effects of CRISPR technology
    • 5.1.3. Opportunities
      • 5.1.3.1. Evolution of anti-CRISPR protein
      • 5.1.3.2. Research and development for novel application of CRISPR-Cas genes
    • 5.1.4. Challenges
      • 5.1.4.1. Patent landscape and dispute
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. CRISPR & Cas Genes Market, by Component

  • 6.1. Introduction
  • 6.2. Product
    • 6.2.1. Antibodies
    • 6.2.2. Design Tool
    • 6.2.3. Kits & Enzymes
      • 6.2.3.1. DNA-Free Cas
      • 6.2.3.2. Vector-Based Cas
    • 6.2.4. Libraries
  • 6.3. Service
    • 6.3.1. Cell Line Engineering
    • 6.3.2. DNA Synthesis
    • 6.3.3. gRNA Design
    • 6.3.4. Microbial Gene Editing

7. CRISPR & Cas Genes Market, by Application

  • 7.1. Introduction
  • 7.2. Agricultural
  • 7.3. Biomedical
    • 7.3.1. Disease Model Studies
    • 7.3.2. Epigenetics
    • 7.3.3. Functional Genomics
    • 7.3.4. Genome Engineering

8. CRISPR & Cas Genes Market, by End-user

  • 8.1. Introduction
  • 8.2. Academics & Government Research Institutes
  • 8.3. Biotechnology & Pharmaceutical Companies
  • 8.4. Contract Research Organizations

9. Americas CRISPR & Cas Genes Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific CRISPR & Cas Genes Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa CRISPR & Cas Genes Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca plc
  • 2. Beam Therapeutics Inc.
  • 3. Beckman Coulter, Inc.
  • 4. Calyxt, Inc.
  • 5. Caribou Biosciences, Inc.
  • 6. CRISPR Therapeutics AG
  • 7. Danaher Corporation
  • 8. Editas Medicine, Inc.
  • 9. Hera Biolabs
  • 10. Horizon Discovery Group Plc
  • 11. Inscripta, Inc.
  • 12. Integrated Dna Technologies, Inc.
  • 13. Intellia Therapeutics, Inc.
  • 14. Lonza Group
  • 15. Mammoth Biosciences
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦